sirolimus + prednisone

The combination of sirolimus and prednisone is a therapeutic approach used primarily for treating retroperitoneal fibrosis (RPF) and in transplant medicine, particularly for chronic graft-versus-host disease. This combination therapy involves administering both medications together, often with a specific dosing strategy that includes a gradual reduction of prednisone while maintaining a stable dosage of sirolimus. **Therapeutic Use in Retroperitoneal Fibrosis** Retroperitoneal fibrosis is a rare autoimmune disease characterized by fibrous tissue growth and inflammation. The combined therapy of sirolimus and prednisone has shown promising results in clinical trials for RPF treatment. A typical protocol involves Prednisone with a gradual taper and Sirolimus at a stable dose (e.g., 2 mg/day initially, then 1 mg/day). Clinical studies have demonstrated significant benefits in RPF: - Reduction of fibrous tissue mass - Decrease in markers of acute inflammation - Restoration of normal kidney function in affected patients - Reduction in fibrosis-related T cell subsets - Restoration of tumor necrosis factor and related cytokines to healthy levels **Mechanism of Action** - **Sirolimus (Rapamycin)**: An mTOR inhibitor, targeting pathways involved in RPF. - **Prednisone**: A glucocorticoid that helps control inflammation. **Pharmacokinetic Interactions** Studies suggest a slight interaction, where prednisolone elimination decreases when administered with sirolimus, leading to increases in Cmax and terminal half-life and decreases in apparent clearance. **Use in Transplant Medicine** This combination is also used, such as for chronic graft-versus-host disease, potentially offering an easier and better-tolerated alternative to regimens including calcineurin inhibitors.

Brand names

RapamuneFyarroHyftorprednisone

Other names

prednisone + rapamycin